Novo Nordisk’s Ozempic, an injectable GLP-1 receptor agonist drug, achieved its primary goal in a Phase 3b study of type 2 diabetes patients already on treatment with an SGLT-2 inhibitor, proving more effective than placebo in lowering blood sugar. Ozempic also achieved the study’s secondary goal, helping patients lose more weight over 30 weeks than those on placebo. Read more